Technology Prognosis

tracking technologies before you have to make a decision

Prognosis is a horizon scanning service that monitors emerging health technologies as they go through clinical trial development and the regulatory approval process.

View a sampling of our Prognosis reports.

Organ Care System (OCS) Lung

May 24, 2017 Technology Prognosis

The Organ Care System (OCS) Lung is a portable organ perfusion, ventilation, and monitoring medical device intended to preserve donor lungs in a near physiologic, ventilated, and perfused state for transplantation. Commonly referred to as the “lung in a box,” it is a portable device on a removable mobile base that integrates a wireless monitor, perfusion module, ventilator, batteries, gas cylinders, and proprietary solutions for organ maintenance. The lung is removed from the donor and immediately attached to the OCS Lung, which perfuses and ventilates the organ. The transplant team is able to continuously monitor lung function during transport and...

Kevzara (Sarilumab)

May 24, 2017 Technology Prognosis

Kevzara is an injectable fully human monoclonal antibody directed against the interleukin-6 (IL-6) receptor for the treatment of moderately to severely active rheumatoid arthritis in adults who have had an inadequate response or are intolerant to 1 or more disease-modifying antirheumatic drugs (DMARDs). Proinflammatory cytokines such as IL-6 are linked to the disease process in RA and play a critical role in joint destruction; the IL-6 receptor has been identified as a potential target for RA therapies.

dermaPACE System for Diabetic Foot Ulcers

May 15, 2017 Technology Prognosis

The dermaPACE system is a noninvasive medical device proposed as an adjunct to standard wound care options to promote healing of diabetic foot ulcers. The dermaPACE device delivers a proprietary type of extracorporeal shock wave therapy (ESWT) known as Pulsed Acoustic Cellular Expression (PACE) therapy. The system consists of an electro-hydraulic generator and wave applicator that is glided over the target ulcer extending 1.0 cm in each direction. Treatment with dermaPACE is typically provided in physician’s office or outpatient healthcare facility, as an adjunct to standard wound care therapy.

Radicava (Edaravone)

May 10, 2017 Technology Prognosis

Radicava is a newly FDA-approved intravenously administered free radical scavenger for the treatment of amyotrophic lateral sclerosis (ALS). Oxidative stress has been considered to be involved in the onset and progression of ALS; it’s postulated that elimination of free radicals might protect motor neurons from oxidative stress and free radical damage in ALS patients. However, the FDA label for Radicava notes that the mechanism by which the drug exerts its therapeutic effect in patients with ALS is unknown. 

Senhance Surgery System for Robotic Surgery

May 8, 2017 Technology Prognosis

The Senhance Surgery System (formerly Telelap ALF-X) is a robotic surgery platform intended for use in laparoscopic surgery. The Senhance system is the first robotic system that brings haptic force feedback to robotic surgery. This feature enables the surgeon to feel the level of force applied during delicate tasks, and is proposed to lead to improved safety and allow certain maneuvers to be performed with greater confidence. The system also tracks the surgeon’s eye movements, positioning the camera so the field of view is centered where the eyes are looking.